

Adcetris® (brentuximab vedotin) – New indication

- On November 10, 2022, <u>Seagen announced</u> the FDA approval of <u>Adcetris (brentuximab vedotin)</u>, for the treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
- Adcetris is also approved for adult patients for previously untreated stage III or IV cHL, in combination with chemotherapy; cHL consolidation; relapsed cHL; previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas, in combination with chemotherapy; relapsed sALCL; relapsed primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides.
- The approval of Adcetris for the new indication was based on AHOD1331, a randomized, openlabel, active-controlled study in 600 pediatric patients (2 to < 22 years of age) with previously untreated high risk cHL. Patients were randomized to Adcetris + doxorubicin [A], vincristine [V], etoposide [E], prednisone [P], cyclophosphamide [C] (ADCETRIS + AVEPC) or to A+ bleomycin [B]+V+E+P+C (ABVE-PC). Efficacy was established based on event-free-survival (EFS), defined as the time from randomization to the earliest of disease progression or relapse, second malignancy, or death due to any cause.
 - Patients had a 59% reduction in the risk of disease progression or relapse, second cancer or death (hazard ratio 0.41; 95% CI: 0.25, 0.67; p = 0.0002).
- Adcetris carries a boxed warning for progressive multifocal leukoencephalopathy.
- The recommended dose of Adcetris for the treatment of pediatric patients with previously untreated high risk cHL is 1.8 mg/kg intravenously up to a maximum of 180 mg in combination with chemotherapy. Adcetris should be administered every 3 weeks with each cycle of chemotherapy for a maximum of 5 doses.
 - Refer to the Adcetris drug label for dosing for all its other indications.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.